Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation
NCT ID: NCT00281554
Last Updated: 2008-04-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
254 participants
INTERVENTIONAL
2005-10-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
RSD1235
IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSD1235
IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must have adequate anticoagulant therapy
Exclusion Criteria
* Subject may not have uncorrected electrolyte imbalance.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Advanz Pharma
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Astellas Pharma US, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntsville, Alabama, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Oak Lawn, Illinois, United States
Boston, Massachusetts, United States
Lansing, Michigan, United States
Austin, Texas, United States
San Antonio, Texas, United States
Richmond, Virginia, United States
Marshfield, Wisconsin, United States
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Corrientes, , Argentina
De Buenos Aires, , Argentina
Rosario, , Argentina
Tulunaw, , Argentina
Calgary, Alberta, Canada
Ottawa, Ontario, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Terrebonne, Quebec, Canada
Aalborg, , Denmark
Esbjerg, , Denmark
Hjørring, , Denmark
Hvidovre, , Denmark
København NV, , Denmark
Køge, , Denmark
Berea Durban, , South Africa
Bloemfontein, , South Africa
Centurion, , South Africa
Parow, , South Africa
Somerset West, , South Africa
Westdene Bloemfontein, , South Africa
Malmo, , Sweden
Mölndal, , Sweden
Örebro, , Sweden
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med. 2010 Nov;17(11):1175-82. doi: 10.1111/j.1553-2712.2010.00915.x.
Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010 Jun;159(6):1095-101. doi: 10.1016/j.ahj.2010.02.035.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-7-012
Identifier Type: -
Identifier Source: org_study_id